{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:01Z","timestamp":1792629541126,"version":"4.5.0"},"reference-count":98,"publisher":"Informa UK Limited","issue":"27","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2217\/fon-2021-1567","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:00:27Z","timestamp":1661418027000},"page":"3085-3100","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1\u03b2 and PD-1 Inhibition"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-6749","authenticated-orcid":false,"given":"Jay M","family":"Lee","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA,\rLos Angeles,\rCA 90095-7313,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5807","authenticated-orcid":false,"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East,\rKashiwanoha,\rKashiwa,\rChiba,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8351-1196","authenticated-orcid":false,"given":"Edward S","family":"Kim","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute,Atrium Health,\rCharlotte,\rNC 28204,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-0551","authenticated-orcid":false,"given":"Tony SK","family":"Mok","sequence":"additional","affiliation":[{"name":"State Key Laboratory of South China,The Chinese University of Hong Kong,\rHong Kong,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[{"name":"Medical Oncology Department,Hospital Ram\u00f3n y Cajal,\rMadrid,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f387e4"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1272867"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp127"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.057"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3477"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31537"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80004"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.01.004"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0123-y"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847575"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.021"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0167-x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.03.15"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.02.007"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.06.021"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.010"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176009"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.12.040"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11276"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.02.022"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081207"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.11.010"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01197"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12621"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mgene.2013.12.002"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-0925-6"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0960"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13042"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.015"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0413"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0158"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172264"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.907524"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.12.021"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175053"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.284"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202769"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812266115"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.10.011"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.12.8200"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301317"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.028"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100001"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2003.tb01428.x"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57285-y"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2016.08.021"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5521"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.085"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.09.006"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2999"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep35651"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2011.10.001"},{"issue":"3","key":"e_1_3_2_61_1","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y","year":"2020","unstructured":"Han Y , LiuD, LiL. PD-1\/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res.10(3), 727\u2013742 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02392-w"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01643"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0191-1"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1632"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57285-y"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2080"},{"issue":"2","key":"e_1_3_2_69_1","first-page":"330","article-title":"Interleukin-1\u03b2-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte\u2013mediated immune suppression","volume":"70","author":"Takahashi R","year":"2021","unstructured":"Takahashi R , MacchiniM, SunagawaMet al. Interleukin-1\u03b2-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte\u2013mediated immune suppression. Gut70(2), 330\u2013341 (2021).","journal-title":"Gut"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0552"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1610"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e14237"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129353"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32247-X"},{"key":"e_1_3_2_75_1","unstructured":"Novartis Pharmaceuticals . Cardiovascular risk reduction study (reduction in recurrent major CV disease events) (CANTOS) (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01327846"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9124"},{"key":"e_1_3_2_78_1","unstructured":"Novartis Pharmaceuticals . Study of efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages AJCC\/UICC v. 8 II-IIIA and IIIB (T>5 cm N2) completely resected non-small-cell lung cancer: CANOPY-A (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03447769"},{"key":"e_1_3_2_79_1","unstructured":"Novartis . Novartis provides update on phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small-cell lung cancer (2021). www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-study-evaluating-canakinumab-acz885-second-or-third-line-treatment-combination-chemotherapy-non-small-cell-lung-cancer"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz437.057"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1098"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-C100"},{"key":"e_1_3_2_83_1","unstructured":"Novartis Phamaceuticals . Novartis top-line results for CANOPY-1 phase III study support further evaluation of canakinumab in lung cancer (2021). www.novartis.com\/news\/media-releases\/novartis-top-line-results-canopy-1-phase-iii-study-support-further-evaluation-canakinumab-lung-cancer"},{"key":"e_1_3_2_84_1","unstructured":"ClinicalTrials.gov . Effect of canakinumab or pembrolizumab given as monotherapy or in combination as neo-adjuvant treatment for subjects with early stages NSCLC (2022). www.clinicaltrials.gov\/ct2\/show\/NCT03968419"},{"key":"e_1_3_2_85_1","unstructured":"ClinicalTrials.gov . Isunakinra alone and in combination with a PD-1\/PD-L1 inhibitor in patients with solid tumors (2021). www.clinicaltrials.gov\/ct2\/show\/NCT04121442"},{"key":"e_1_3_2_86_1","unstructured":"ClinicalTrials.gov . Anakinra in treating patients with metastatic cancer expressing the interleukin-1 gene (2015). www.clinicaltrials.gov\/ct2\/show\/NCT00072111"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.01.010"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1761"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86941-5"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0458-x"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr216"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0454"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.2123"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082319"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827788"},{"key":"e_1_3_2_99_1","first-page":"e448","article-title":"Residual inflammatory risk and residual cholesterol risk: critical analysis from the CANTOS trial","volume":"136","author":"Ridker PM","year":"2017","unstructured":"Ridker PM , LibbyP, GlynnRJ. group ObotCts. Residual inflammatory risk and residual cholesterol risk: critical analysis from the CANTOS trial. Circulation136, e448\u2013e467 (2017).","journal-title":"Circulation"},{"key":"e_1_3_2_100_1","unstructured":"Dobkowski D . CANTOS: magnitude of CRP reduction linked with canakinumab clinical benefit (2017). www.healio.com\/news\/cardiology\/20171113\/cantos-magnitude-of-crp-reduction-linked-with-canakinumab-clinical-benefit"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:24Z","timestamp":1719125184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":98,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2217\/fon-2021-1567"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1567","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}